Cold agglutinin disease
(Redirected from Idiopathic cold hemagglutinin syndrome)
A rare autoimmune disorder affecting red blood cells
Cold agglutinin disease | |
---|---|
![]() | |
Synonyms | Cold autoimmune hemolytic anemia, CAD |
Pronounce | |
Field | Hematology, Immunology |
Symptoms | Fatigue, anemia, jaundice, cold-induced acrocyanosis, Raynaud's phenomenon |
Complications | Hemolytic anemia, splenomegaly, circulatory collapse in severe cases |
Onset | Often insidious; more common in older adults |
Duration | Chronic (primary) or transient (secondary) |
Types | Primary (idiopathic), Secondary (due to infection, malignancy, or autoimmune disease) |
Causes | Autoantibodies targeting red blood cells, often triggered by cold temperatures |
Risks | Mycoplasma pneumoniae infection, Epstein–Barr virus, lymphoma, autoimmune diseases |
Diagnosis | Direct antiglobulin test (Coombs test), Cold agglutinin titer, blood smear, complete blood count |
Differential diagnosis | Warm autoimmune hemolytic anemia, paroxysmal cold hemoglobinuria, cryoglobulinemia |
Prevention | Avoidance of cold exposure, treating underlying conditions |
Treatment | Warm clothing, rituximab, corticosteroids, plasmapheresis in severe cases |
Medication | Rituximab, bendamustine, cyclophosphamide, folic acid supplements |
Prognosis | Generally good with treatment; variable in secondary disease depending on underlying cause |
Frequency | Rare; estimated incidence of 1 per million per year |
Deaths | Rare, mostly in severe untreated or complicated cases |
Cold agglutinin disease (CAD) is a rare autoimmune disorder characterized by the presence of cold agglutinins, which are antibodies that cause red blood cells to clump together at low temperatures. This clumping can lead to the destruction of red blood cells, a condition known as hemolytic anemia.
Pathophysiology[edit | edit source]
Cold agglutinin disease is primarily mediated by IgM antibodies that target the I antigen on the surface of red blood cells. These antibodies are most active at temperatures below normal body temperature, typically between 0°C and 30°C. When exposed to cold, these antibodies bind to red blood cells, causing them to agglutinate, or clump together. This agglutination can lead to the activation of the complement system, resulting in the destruction of red blood cells through a process called intravascular hemolysis.
Clinical Presentation[edit | edit source]
Patients with cold agglutinin disease often present with symptoms of anemia, such as fatigue, pallor, and shortness of breath. In addition, exposure to cold temperatures can lead to acrocyanosis, a bluish discoloration of the extremities, and Raynaud's phenomenon, where fingers and toes change color in response to cold or stress. Some patients may also experience hemoglobinuria, which is the presence of hemoglobin in the urine, giving it a dark color.
Diagnosis[edit | edit source]
The diagnosis of cold agglutinin disease is based on clinical presentation and laboratory findings. A complete blood count may reveal anemia, and a direct antiglobulin test (DAT) is often positive for complement. The presence of cold agglutinins can be confirmed by testing the patient's serum at different temperatures to observe agglutination of red blood cells. A cold agglutinin titer may also be performed to quantify the level of cold agglutinins.
Treatment[edit | edit source]
Management of cold agglutinin disease involves avoiding exposure to cold temperatures to prevent hemolysis. In severe cases, treatment may include immunosuppressive therapy such as rituximab, a monoclonal antibody that targets B cells, or other agents like corticosteroids. In some cases, plasmapheresis may be used to remove antibodies from the blood. Patients with significant anemia may require blood transfusions.
Prognosis[edit | edit source]
The prognosis for patients with cold agglutinin disease varies. Some individuals may experience mild symptoms and require minimal intervention, while others may have more severe disease requiring ongoing treatment. The condition is typically chronic, and management focuses on symptom control and prevention of complications.
Related pages[edit | edit source]
External links[edit | edit source]
Classification | |
---|---|
External resources |
|
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Kondreddy Naveen, Prab R. Tumpati, MD